Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

NCT04149691 is registered in ClinicalTrials.gov with Celon Pharma SA as lead sponsor.

NCT NCT04149691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04149691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Lead sponsor
Celon Pharma SA
Phase
Phase 1
Overall status
Unknown status
Start date
July 19, 2019
Completion date
June 30, 2024
Enrollment
42 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cholangiocarcinoma, endometrial cancer, gastric cancer, other solid tumours, sarcoma, squamous non-small cell lung cancer